Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Identifieur interne : 003C04 ( PubMed/Curation ); précédent : 003C03; suivant : 003C05Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Auteurs : Maria C. Obinu [France] ; Michel Reibaud ; Véronique Blanchard ; Saliha Moussaoui ; Assunta ImperatoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Animals, Behavior, Animal (drug effects), Callithrix, Disease Models, Animal, Dopamine (metabolism), Dopamine Agents (adverse effects), Female, Immunohistochemistry, Locomotion (drug effects), Male, Neuroprotective Agents (pharmacology), Neuroprotective Agents (therapeutic use), Nissl Bodies (drug effects), Nissl Bodies (metabolism), Nissl Bodies (pathology), Parkinson Disease (drug therapy), Parkinson Disease, Secondary (chemically induced), Random Allocation, Riluzole (pharmacology), Riluzole (therapeutic use), Substantia Nigra (drug effects).
- MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Dopamine Agents.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal, Locomotion, Nissl Bodies, Substantia Nigra.
- drug therapy : Parkinson Disease.
- chemical , metabolism : Dopamine, Nissl Bodies.
- pathology : Nissl Bodies.
- chemical , pharmacology : Neuroprotective Agents, Riluzole.
- chemical , therapeutic use : Neuroprotective Agents, Riluzole.
- Animals, Callithrix, Disease Models, Animal, Female, Immunohistochemistry, Male, Random Allocation.
Abstract
Our study aimed to determine whether riluzole, which has shown efficacy as a disease-modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective strategy with good tolerability. The efficacy of riluzole was evaluated in marmosets by testing its ability to reduce MPTP-induced behavioral deficits and loss of dopaminergic nigral neurons. Marmosets were divided into two groups of four animals each: animals in Group 1 were injected twice with MPTP (2 mg/kg subcutaneous) and treated with riluzole (10 mg/kg per os b.i.d.), animals in Group 2 (controls) were injected with MPTP and with the vehicle of riluzole. A third group of marmosets which did not receive MPTP or riluzole drug was introduced for neurohistopathological studies (normal animals). Marmosets treated with riluzole preserved a better motor function and neurological performance through the 26 days of assessment when compared with the controls. Histologically, there was sparing of TH- and Nissl-stained nigral neurons and of TH-stained terminals in the striatum and the putamen in the group treated with riluzole compared to the controls. We conclude that riluzole protects dopaminergic neurons and reduces behavioral deficits in a marmoset model of PD.
PubMed: 11835434
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003C04
Links to Exploration step
pubmed:11835434Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.</title>
<author><name sortKey="Obinu, Maria C" sort="Obinu, Maria C" uniqKey="Obinu M" first="Maria C" last="Obinu">Maria C. Obinu</name>
<affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine, France. Marie-Carmen.Obinu@aventis.com</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Reibaud, Michel" sort="Reibaud, Michel" uniqKey="Reibaud M" first="Michel" last="Reibaud">Michel Reibaud</name>
</author>
<author><name sortKey="Blanchard, Veronique" sort="Blanchard, Veronique" uniqKey="Blanchard V" first="Véronique" last="Blanchard">Véronique Blanchard</name>
</author>
<author><name sortKey="Moussaoui, Saliha" sort="Moussaoui, Saliha" uniqKey="Moussaoui S" first="Saliha" last="Moussaoui">Saliha Moussaoui</name>
</author>
<author><name sortKey="Imperato, Assunta" sort="Imperato, Assunta" uniqKey="Imperato A" first="Assunta" last="Imperato">Assunta Imperato</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:11835434</idno>
<idno type="pmid">11835434</idno>
<idno type="wicri:Area/PubMed/Corpus">003C04</idno>
<idno type="wicri:Area/PubMed/Curation">003C04</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.</title>
<author><name sortKey="Obinu, Maria C" sort="Obinu, Maria C" uniqKey="Obinu M" first="Maria C" last="Obinu">Maria C. Obinu</name>
<affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine, France. Marie-Carmen.Obinu@aventis.com</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Reibaud, Michel" sort="Reibaud, Michel" uniqKey="Reibaud M" first="Michel" last="Reibaud">Michel Reibaud</name>
</author>
<author><name sortKey="Blanchard, Veronique" sort="Blanchard, Veronique" uniqKey="Blanchard V" first="Véronique" last="Blanchard">Véronique Blanchard</name>
</author>
<author><name sortKey="Moussaoui, Saliha" sort="Moussaoui, Saliha" uniqKey="Moussaoui S" first="Saliha" last="Moussaoui">Saliha Moussaoui</name>
</author>
<author><name sortKey="Imperato, Assunta" sort="Imperato, Assunta" uniqKey="Imperato A" first="Assunta" last="Imperato">Assunta Imperato</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term>
<term>Animals</term>
<term>Behavior, Animal (drug effects)</term>
<term>Callithrix</term>
<term>Disease Models, Animal</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Female</term>
<term>Immunohistochemistry</term>
<term>Locomotion (drug effects)</term>
<term>Male</term>
<term>Neuroprotective Agents (pharmacology)</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Nissl Bodies (drug effects)</term>
<term>Nissl Bodies (metabolism)</term>
<term>Nissl Bodies (pathology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Random Allocation</term>
<term>Riluzole (pharmacology)</term>
<term>Riluzole (therapeutic use)</term>
<term>Substantia Nigra (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term>
<term>Locomotion</term>
<term>Nissl Bodies</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Nissl Bodies</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Nissl Bodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Random Allocation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Our study aimed to determine whether riluzole, which has shown efficacy as a disease-modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective strategy with good tolerability. The efficacy of riluzole was evaluated in marmosets by testing its ability to reduce MPTP-induced behavioral deficits and loss of dopaminergic nigral neurons. Marmosets were divided into two groups of four animals each: animals in Group 1 were injected twice with MPTP (2 mg/kg subcutaneous) and treated with riluzole (10 mg/kg per os b.i.d.), animals in Group 2 (controls) were injected with MPTP and with the vehicle of riluzole. A third group of marmosets which did not receive MPTP or riluzole drug was introduced for neurohistopathological studies (normal animals). Marmosets treated with riluzole preserved a better motor function and neurological performance through the 26 days of assessment when compared with the controls. Histologically, there was sparing of TH- and Nissl-stained nigral neurons and of TH-stained terminals in the striatum and the putamen in the group treated with riluzole compared to the controls. We conclude that riluzole protects dopaminergic neurons and reduces behavioral deficits in a marmoset model of PD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11835434</PMID>
<DateCreated><Year>2002</Year>
<Month>02</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>2002</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>17</Volume>
<Issue>1</Issue>
<PubDate><Year>2002</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.</ArticleTitle>
<Pagination><MedlinePgn>13-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Our study aimed to determine whether riluzole, which has shown efficacy as a disease-modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective strategy with good tolerability. The efficacy of riluzole was evaluated in marmosets by testing its ability to reduce MPTP-induced behavioral deficits and loss of dopaminergic nigral neurons. Marmosets were divided into two groups of four animals each: animals in Group 1 were injected twice with MPTP (2 mg/kg subcutaneous) and treated with riluzole (10 mg/kg per os b.i.d.), animals in Group 2 (controls) were injected with MPTP and with the vehicle of riluzole. A third group of marmosets which did not receive MPTP or riluzole drug was introduced for neurohistopathological studies (normal animals). Marmosets treated with riluzole preserved a better motor function and neurological performance through the 26 days of assessment when compared with the controls. Histologically, there was sparing of TH- and Nissl-stained nigral neurons and of TH-stained terminals in the striatum and the putamen in the group treated with riluzole compared to the controls. We conclude that riluzole protects dopaminergic neurons and reduces behavioral deficits in a marmoset model of PD.</AbstractText>
<CopyrightInformation>Copyright 2001 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Obinu</LastName>
<ForeName>Maria C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo><Affiliation>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine, France. Marie-Carmen.Obinu@aventis.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Reibaud</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Blanchard</LastName>
<ForeName>Véronique</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moussaoui</LastName>
<ForeName>Saliha</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Imperato</LastName>
<ForeName>Assunta</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber>
<NameOfSubstance UI="D019782">Riluzole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9P21XSP91P</RegistryNumber>
<NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001522">Behavior, Animal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002144">Callithrix</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008124">Locomotion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009562">Nissl Bodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011897">Random Allocation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019782">Riluzole</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>2</Month>
<Day>9</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2002</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>2</Month>
<Day>9</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11835434</ArticleId>
<ArticleId IdType="pii">10.1002/mds.1272</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003C04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:11835434 |texte= Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:11835434" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |